Form 4: NeoGenomics Executive Reports Routine Stock Transaction
Insider Transaction Report
NeoGenomics EVP Alicia Olivo reported a disposition of 1,666 common shares to cover tax obligations from restricted stock vesting.
Summary
- Alicia C. Olivo, Executive Vice President, General Counsel & Business Development of NeoGenomics, Inc. (NEO), reported a transaction involving company securities.
- On September 1, 2025, 1,666 shares of NeoGenomics common stock were surrendered to the company for retirement.
- This disposition was made to satisfy tax obligations incurred in connection with the vesting of restricted stock on the same date.
- Following this reported transaction, Ms. Olivo directly beneficially owns 47,940 shares of common stock.
- Ms. Olivo also holds various derivative securities, including stock options with exercise prices ranging from $9.45 to $48.99, restricted stock units, and performance stock units, with different grant and vesting schedules.
Sentiment
Score: 5
Explanation: Neutral. This is a routine compliance filing detailing an executive's equity compensation transaction, which is neither inherently positive nor negative for the company's operational or financial performance.
Positives
- The transaction is a routine event related to the vesting of equity compensation, indicating the executive's continued long-term incentive alignment with the company.
- The executive retains a significant number of common shares (47,940) and substantial derivative holdings, demonstrating continued vested interest in the company's performance.
Negatives
- A disposition of shares, even for tax purposes, reduces the executive's direct common stock ownership.
Risks
- No specific risks are mentioned in this Form 4 filing beyond the general market risks associated with holding equity.
Future Outlook
NA
Industry Context
NA
Stakeholder Impact
- Shareholders: Minor, as the transaction is a routine tax-related disposition of a small number of shares by an executive. It confirms the executive's continued equity holdings and alignment.
- Employees: No direct impact.
- Management: The transaction reflects standard equity compensation practices for executives.
Next Steps
- Continued vesting of various stock options, restricted stock units, and performance stock units held by Ms. Olivo according to their respective schedules.
Key Dates
| Date | Description |
|---|---|
| 2019-09-30 | Grant date for 1,394 stock options. |
| 2020-05-01 | Grant date for 1,024 stock options. |
| 2021-05-01 | Grant date for 516 stock options. |
| 2021-08-01 | Grant date for 1,117 stock options. |
| 2022-05-01 | Grant date for 22,222 stock options. |
| 2022-09-01 | Grant date for 55,332 stock options. |
| 2023-05-11 | Grant date for 36,508 stock options, 19,508 restricted stock units, and 19,508 performance stock units. |
| 2024-02-23 | Grant date for 42,344 stock options, 25,330 performance stock units, and 25,329 restricted stock units. |
| 2025-02-21 | Grant date for 107,450 stock options and 63,238 restricted stock units. |
| 2025-09-01 | Transaction date for disposition of 1,666 common shares to satisfy tax obligations from restricted stock vesting. |
| 2026-01-13 | Vesting date for 59,382 Restricted Stock Units. |
| 2026-05-11 | Vesting date for 19,508 Performance Stock Units. |
| 2026-09-30 | Expiration date for 1,046 stock options. |
| 2027-02-23 | Vesting date for 25,330 Performance Stock Units. |
| 2027-05-01 | Expiration date for 1,024 stock options. |
| 2028-05-01 | Expiration date for 516 stock options. |
| 2028-08-01 | Expiration date for 1,117 stock options. |
| 2029-05-01 | Expiration date for 22,222 stock options. |
| 2029-09-01 | Expiration date for 55,332 stock options. |
| 2030-05-11 | Expiration date for 36,508 stock options. |
| 2034-02-23 | Expiration date for 42,344 stock options. |
| 2035-02-21 | Expiration date for 107,450 stock options. |
Keywords
NeoGenomics, NEO, Alicia Olivo, Form 4, Insider Transaction, Stock Options, Restricted Stock Units, Performance Stock Units, Equity Compensation, Beneficial Ownership
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.